MabVax Therapeutics Holdings Inc

MabVax Therapeutics — Investor Presentation (February 2016)

30 slides from MabVax Therapeutics's investor presentation, Feb 12, 2016

  1. Slide 1: February 2016 Corporate Presentation

    Slide 1: February 2016 Corporate Presentation

    M MabVax —_ therapeutics IMMUNO-ONCOLOGY DISCOVERY & DEVELOPMENT COMPANY February 2016 Corporate Presentation David Hansen President and CEO

  2. Slide 2: Disclaimer: Forward Looking Statements

    Slide 2: Disclaimer: Forward Looking Statements

    DISCLAIMER Forward Looking Statements ‘This presentation contains forward-looking statements and projections. ‘The company makes ‘no is information or, in the its own independent investigation, It must be recognized that estimates of the company’s performance are neces subject to a high degree of un

  3. Slide 3: MabVax Highlights — Progress Over Last Few Months

    Slide 3: MabVax Highlights — Progress Over Last Few Months

    MABVAX HIGHLIGHTS —PROGRESS OVER LAST FEW MONTHS ¢ FDA authorization for two Phase I trials starting this quarter ¥ Phase I Trial of HuMab-5B1 as therapeutic monoclonal antibody for pancreatic and G.1. cancers * Filed IND November 30, 2015 and received FDA authorization on December 24 © First patien

  4. Slide 4: Differentiated Immuno-Oncology Discovery Platform

    Slide 4: Differentiated Immuno-Oncology Discovery Platform

    DIFFERENTIATED IMMUNO-ONCOLOGY DISCOVERY PLATFORM Novel Targets Novel Therapies Significant Market Opportunity Complementary Immuno- Oncology Technologies Myenvex Tumor-associated carbohydrate antigens present ideal targets for antibody-based therapy Unique discovery process has resulted in portfoli

  5. Slide 5: Antibody Discovery Platform Leverages Immune Response From Many Vaccinated Patients

    Slide 5: Antibody Discovery Platform Leverages Immune Response From Many Vaccinated Patients

    ANTIBODY DISCOVERY PLATFORM LEVERAGES IMMUNE RESPONSE FROM MANY VACCINATED PATIENTS 4 Vaccine Given £ Multiple Times ali) = Pomenepome Multiple Patients (Range 7 to 68) rates Best Antibodies Identified _ IM Te scanty Cloned & Expressed ‘As Monoclonal Maye vai oat Paes korn Ronee to Vaecine Patient R

  6. Slide 6: Lead Antibody Program — HuMab-5B1

    Slide 6: Lead Antibody Program — HuMab-5B1

    LEAD ANTIBODY PROGRAM — HUMAB-5B1 ANTIGEN EXPRESSED ON MULTIPLE SOLID TUMOR CANCERS OH O<-OH s @ CA19.9 also known as Sialyl Lewis* OH yn’ 2 : 070 on ~ Larget is the most es studied and clinically HO on useful biomarker for pancreatic cancer HO te) OH - High copy numbers on cancer cell membrane make

  7. Slide 7: Preclinical Results Demonstrate Significant Potential of HuMab-5B1 as Targeting Platform

    Slide 7: Preclinical Results Demonstrate Significant Potential of HuMab-5B1 as Targeting Platform

    PRECLINICAL RESULTS DEMONSTRATE SIGNIFICANT POTENTIAL OF HUMAB-5B1 AS TARGETING PLATFORM Development Target Specificity Enables Complimentary Precision Medicine Products M MabVax ooe ° oe Remarkable target antigen specificity and affinity ‘Toxicology results from GLP primate studies demonstrate clea

  8. Slide 8: HuMab-5B1 Antibody Target Significantly Overexpressed on Multiple Cancers

    Slide 8: HuMab-5B1 Antibody Target Significantly Overexpressed on Multiple Cancers

    HUMAB-5B1 ANTIBODY TARGET SIGNIFICANTLY OVEREXPRESSED ON MULTIPLE CANCERS Pancreas, ductal Sigmoid colon, Lung, adenocarcinoma, carcinoma stage IB (1) Stage I lymph node, metastatic carcinoma , IA.

  9. Slide 9: Minimal Staining in Normal Tissues Enhances Safety Profile

    Slide 9: Minimal Staining in Normal Tissues Enhances Safety Profile

    MINIMAL STAINING IN NORMAL TISSUES ENHANCES SAFETY PROFILE Brain neg Breast + Colon + kidney neg. iver neg. Lung neg. Lymph node neg. Muscle neg. Pancreas + Placenta neg, ‘Skin neg. Spleen neg. Stomach neg Unpublished data. Allwork done at Pathology Department MSKCC Myenvex . . . . Positive cells ar

  10. Slide 10: HuMab-5B1 Demonstrates Substantial Potentiation of Anti-Tumor Effect of SOC Chemotherapy

    Slide 10: HuMab-5B1 Demonstrates Substantial Potentiation of Anti-Tumor Effect of SOC Chemotherapy

    HUMAB-5B1 DEMONSTRATES SUBSTANTIAL POTENTIATION OF ANTI- TUMOR EFFECT OF SOC CHEMOTHERAPY IN PANCREATIC CANCER Relative Tumor Growth at Day 42 Gemcitabine/nab-Paclitaxel as Baseline BxPC3 Xenograft Model Growth Relative to Control (%)

  11. Slide 11: HuMab-5B1 Demonstrates Substantial Anti-Tumor Effect in Small Cell Lung Cancer Model

    Slide 11: HuMab-5B1 Demonstrates Substantial Anti-Tumor Effect in Small Cell Lung Cancer Model

    HUMaAaB-5B1 DEMONSTRATES SUBSTANTIAL ANTI-TUMOR EFFECT IN SMALL CELL LUNG CANCER MODEL Relative Tumor Volume at Day 52 Compared to IgG Control DMS 79 Xenograft Model: Hu IgG Control and Active Treatment Groups Volume Relative to Control (%)

  12. Slide 12: PET Imaging of Human Colon, Pancreatic & SCLC Xenografts in SCID Mice

    Slide 12: PET Imaging of Human Colon, Pancreatic & SCLC Xenografts in SCID Mice

    897 R-HUMAB-5B1 PET IMAGING OF HUMAN COLON, PANCREATIC & SCLC XENOGRAFTS IN SCID MICE PET maximum intensity projections of mice-bearing colo205 (A), BxPC3 (B), and DMS79 (C) xenografts showing delincation of tumor (I) by §°Z1-HuMab-5B1. All work done in collaboration with and in the lab of Jason S.

  13. Slide 13: HuMab-5B1-PET Improves Imaging Compared to Standard Agent in Use Today

    Slide 13: HuMab-5B1-PET Improves Imaging Compared to Standard Agent in Use Today

    HUMAB-5B1-PET IMPROVES IMAGING COMPARED TO STANDARD AGENT IN USE TODAY planted with BxPC34 Journal of Nuclear Medicine (Now: 2013) NUCI ‘09 Acquied "2 etilabed-5B1 anbody (2-581) DPT image of the same mouse co-egitered with CCT exhibited exceptional tumor detection of the ‘metabolic issues Received

  14. Slide 14: Dose Selection and Biodistribution of HuMab-5B1 RIT

    Slide 14: Dose Selection and Biodistribution of HuMab-5B1 RIT

    Dose Selection and Biodistribution of HuMab-5B1 RIT . 377Lu-CHX-A"-DTPA-5B1. i of 77 Lu-CHX-A”-DTPA-5B1. N=8 for all groups ‘Normalized Tumor Volume Tine on) LSS SEP E Key points from xenograph studies: + Excellent tumor targeting with minimal impact on non-cancerous tissues + SB1-based RIT agents v

  15. Slide 15: Feasibility Established for 5B1-Toxin Conjugates

    Slide 15: Feasibility Established for 5B1-Toxin Conjugates

    FEASIBILITY ESTABLISHED FOR 5B1-TOXIN CONJUGATES BrdU Cell Proliferation Assay with BxPC3 and Colo205 Cells. WST-I Assay with Jurkat Cells As Control : vam oft SBI-Toxin ADC demonstrates potent i vitro and in vivo eytotoxicity in two pancreatic cell lines known to express sialyl Lewis? Encouraging t

  16. Slide 16: Phase I Trial of HuMab-5B1 in PDAC & CA19-9 Positive Cancer

    Slide 16: Phase I Trial of HuMab-5B1 in PDAC & CA19-9 Positive Cancer

    PHASE I TRIAL OF HUMAB-5B1 IN PDAC & CA19-9 POSITIVE _CANCER Open label, ized, dose escalation/expansion study conducted by MabVax Multicenter, US only, enrollment February 2016, indicated in pancreatic adenocarcinoma (PDAC) . ing doses of HuMab-5B1 followed by expansion at MTD in 10 subje is Single

  17. Slide 17: Phase I Trial of [Zr-89]-HuMab-5B1 in Pancreatic Cancer

    Slide 17: Phase I Trial of [Zr-89]-HuMab-5B1 in Pancreatic Cancer

    PHASE I TRIAL OF [ZR-89]-HUMAB-5B1 IN PANCREATIC CANCER Open label, ized, dose escalation/expansion study conducted by MabVax . Multicenter, US only, enrollment (planned) April 2016 pancreatic cancer and CA19-9 Positive . Dose escalation evaluates adding increasing doses of HuMab-5B1 to improve PE'T

  18. Slide 18: Pancreatic Ductal Adenocarcinoma & HuMab-5B1

    Slide 18: Pancreatic Ductal Adenocarcinoma & HuMab-5B1

    PANCREATIC DUCTAL ADENOCARCINOMA & HUMAB-5B1 * Dismal prognosis for PDAC — Fourth leading cause of cancer death today growing to second overall by 2020 — Five year survival rate is less than 10% — Resection is only cure and only 20% of patients quality for surgery — Five year survival rate post surg

  19. Slide 19: Market Opportunity Focusing on Metastatic Pancreatic and Colon Cancer

    Slide 19: Market Opportunity Focusing on Metastatic Pancreatic and Colon Cancer

    MARKET OPPORTUNITY FOCUSING ON METASTATIC PANCREATIC AND COLON CANCER ith Billion Dollar Potential Therapeutic Product Diagnostic Product . o-¢ - . 96,000 new metastatic pancreatic and colon cancer patients each year 5-year survival rate is less than 10% Most advanced standard of care increases surv

  20. Slide 20: Deals and Value for Early Stage Oncology Antibody Assets Has Dramatically Increased

    Slide 20: Deals and Value for Early Stage Oncology Antibody Assets Has Dramatically Increased

    DEALS AND VALUE FOR EARLY STAGE ONCOLOGY ANTIBODY ASSETS HAS DRAMATICALLY INCREASED Number of Deals: 276 ‘Average Deal Value: $417.83M Average Upfront Payments: $60.41M Average Milestone Payments: $537.37M ata Pharma eTrack. Early stage obi iy deals in oncology. sero 2016 20

  21. Slide 21: Key Milestones for HuMab5B1 Development Program

    Slide 21: Key Milestones for HuMab5B1 Development Program

    KEY MILESTONES FOR HUMAB5B1 DEVELOPMENT PROGRAM EXPECTATIONS FOR 2016 AND 2017 1H 2016 | 2H 2016 | 1H 2017 2H 2017 > Initiate Phase | > Early data readout > Full data readout > Early data inical trial for for safety, dose for Phase | trials readout for Phase therapeutic agent determination, RIT tria

  22. Slide 22: Therapeutic Vaccine Program

    Slide 22: Therapeutic Vaccine Program

    Therapeutic Vaccine Program VACCINATING PATIENTS TO ELICIT A PROTECTIVE ANTIBODY RESP AIMED AT KILLING RESIDUAL DISEASE

  23. Slide 23: Sarcoma Vaccine POC Phase II Results Anticipated 2016

    Slide 23: Sarcoma Vaccine POC Phase II Results Anticipated 2016

    SARCOMA VACCINE POC PHASE II RESULTS ANTICIPATED 2016 ¢ Medical Management Of Recurrent Disease Sarcoma incidence And = 5,290 deaths per year in the U. = Recurrence rat 8: = Canéatitis ante site reeucrenee Suv Current therapies ineffective at preventing recurrence suring ¢ Clinical Program Status ne

  24. Slide 24: Ovarian Vaccine POC Phase II Results Anticipated 2016

    Slide 24: Ovarian Vaccine POC Phase II Results Anticipated 2016

    OVARIAN VACCINE POC PHASE II RESULTS ANTICIPATED 2016 ¢ Medical Management Of Recurrent Disease ‘Ovarian Cancer Incidence and < Prevalence = 13,850 deaths per year in the US. nie80 = Recurrence rate = Current therapies ineffective at preventing recurrence suring ¢ Clinical Program Status sew Cases =

  25. Slide 25: Multiple Deals in Oncology Vaccine Market with Increasing Value in Recent Years

    Slide 25: Multiple Deals in Oncology Vaccine Market with Increasing Value in Recent Years

    MULTIPLE DEALS IN ONCOLOGY VACCINE MARKET WITH INCREASING VALUE IN RECENT YEARS Deal Count: 72 ‘Average Deal Value: $323.27M ‘Average Upfront Payments: $33.99M Average Milestone Payments: $405.07 ‘Source: GlobalData Pharma eTrack. Phase | and Phase Il vaccine deals in oncology therapy. January 2016

  26. Slide 26: Robust Intellectual Property

    Slide 26: Robust Intellectual Property

    ROBUST INTELLECTUAL PROPERTY ¢ issued patents and 3 pending applications in the US. = Issued patents covering monovalent and poly methods of use ent vaccines, methods of manufacture, = 2pending applications covering monoclonal antibodies ¢ 14 international patents and 3 pending applications = Issued

  27. Slide 27: Strong Management Team and Board of Directors

    Slide 27: Strong Management Team and Board of Directors

    STRONG MANAGEMENT TEAM AND BOARD OF DIRECTORS J. David Hansen ‘MabVas, Avie, Nenerex Dur, Schesing Plough, Founder, President & CEO ovens, Du Board Member Key, BMS Philip Livingston, Memoval Som Keneing Cancer Center MD. Founder & Chit Science Officer Gregory Hanson (Chie Financial Officer Wolfgang

  28. Slide 28: Shares Common Stock Outstanding

    Slide 28: Shares Common Stock Outstanding

    SHARES COMMON STOCK OUTSTANDING Meee: /ax Therapeutics Mabvax he fra re ene oe een oc i r shoe) 25,891,075 2,500,000 35391075 Common stock issued and outstanding prior to offering Underwritten offering closing Oct. 5, 2015 (excludes 15% green shoe Total issued and outstanding after closing oan zaps

  29. Slide 29: Differentiated Cancer Immunotherapy Company with Multiple Near-Term Milestones

    Slide 29: Differentiated Cancer Immunotherapy Company with Multiple Near-Term Milestones

    DIFFERENTIATED CANCER IMMUNOTHERAPY COMPANY WITH MULTIPLE NEAR-TERM MILESTONES ° MabVax: Cost-effective discovery and early development of multiple novel products with significant commercial potential - HuMab-5B1 program holds significant potential for multiple targeted therapeutic and diagnostic ap

  30. Slide 30: Company Contacts

    Slide 30: Company Contacts

    Mi MabVax therapeutics IMMUNO-ONCOLOGY DISCOVERY & DEVELOPMENT COMPANY Harnessing the Human Immune System To Diagnose and Treat Cancer Company Contacts David Hansen Gregor President and CEO. Chief Financial Officer gregoryhanson@mabvax.com 858-259-9405 x 303 dhansen@mabvax.com 858-259-9405 x 301

Source: SEC EDGAR · 8-K filed Feb 12, 2016

More decks from MabVax Therapeutics Holdings Inc